CRISPR-Cas9 commercialization may be slowed by delivery and manufacturing challenges
MARK SCHIEFELBEIN/AP
There's great promise in CRISPR-Cas9 gene-editing "drugs" if companies can solve two challenges: how to deliver them to cells and how to make enough.
No hay comentarios:
Publicar un comentario